Technology transfer is a complex technical process that does not often receive the resources or considerations that it needs to ensure success of complex manufacturing processes. Ideally, technology transfer should be managed by a dedicated division or specialist group, which is one of the benefits gained by outsourcing manufacturing projects to an established contract manufacturing organization (CMO). A dedicated team knows that technology transfer programs are not always straightforward, quick, or easy to perform and that there will always be challenges to overcome and problems to resolve to achieve success. Their experience will also have taught them that clients often have very little idea as to what the transfer process involves, which means that the development of a trusting relationship between the client and the CMO is essential.
There are no fool-proof strategies that can guarantee a smooth technology transfer, but certain factors have a large influence on success: meticulous planning, technical understanding of the manufacturing processes, and good communication. A strong emphasis need be placed on a risk-based approach. This involves the identification of risks, both technical and scientific, and logistical, at an early stage, to develop avoidance or mitigation strategies far enough in advance to help keep the transfer program on course. This kind of strategy relies on a highly knowledgeable team of people who have the necessary experience to be able to anticipate the issues that may arise, and excellent communication between the sending and receiving units.
For a CMO, one of the biggest challenges in technology transfer can be dealing with client expectations. For first-timers, the idea of technology transfer can seem quite simple and straightforward: "We've developed this process at our facility—how hard can it be to do the same thing in a new place?" The truth is that even transferring the simplest process will be a complex progression of planning, testing, and optimizing, especially considering that most biotech products being transferred to a CMO will be moving into clinical trials with the intention to eventually manufacture commercially. This should mean that processes are, at this stage, being looked at critically to assess suitability for scale-up and regulatory compliance. Clear communication and the development of a good relationship between both parties is clearly of benefit to all from the very start of the project.